Galit Meshulam-Simon is the associate director of Commercial Applications at Elegen. COVID-19 brought messenger RNA (mRNA) into the global spotlight, demonstrating its speed, flexibility, and efficacy ...
A noninvasive blood test to detect genetic material shed by tumors may help clinicians identify adverse events related to treatment with immune checkpoint inhibitor drugs, investigators at the Johns ...
A novel, blood-based test developed using fragmentomic features of cell-free DNA (cfDNA) detects colorectal cancer (CRC) with a 90.4% sensitivity and shows consistent performance across stages and ...
Advanced lung cancer inflammation index (ALI) as a prognostic marker for locally advanced and metastatic cancer: A prospective study. Phase II study of disitamab vedotin (RC48) in combination with ...
Researchers from Geneseeq and a network of Chinese academic hospitals have validated a blood test that can detect a broad range of cancers with high accuracy using cell-free DNA. A multi-cancer early ...
The future of personalized medicine is rapidly becoming a reality, powered by advances in genetic testing and healthcare. Once limited to research labs, genetic insights are now transforming how ...
Precision medicine in prostate cancer utilizes genetic testing to identify patients for PARP inhibitor treatment, enhancing personalized care. Genetic testing, including germline and somatic, is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results